US FDA's Spikevax Review By The Numbers

A timeline of the development and approval of Moderna's mRNA vaccine, and a listing of FDA reviewers on the biologics license application.

Drug Review Profile: Spikevax Chronology
Moderna's COVID-19 vaccine moved from pre-IND meeting to full approval in less than two years. • Source: Alamy

Elsewhere in this Drug Review Profile, the Pink Sheet examines how the US Food and Drug Administration took the Omicron variant's predominance into account in its review and January approval of Moderna, Inc.'s COVID-19 vaccine Spikevax.(Also see "COVID-19 Vaccines: Spikevax Review Reflected Changing Realities Of Omicron In US" - Pink Sheet, 4 May, 2022.)

Below is the clinical development review timeline and a table of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Review Profiles

More from Product Reviews